Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAvMed Azedra IV Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Azedra (iobenguane I-131) IV — Prior Authorization and Medical Necessity Criteria

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and medical necessity criteria for AvMed coverage of Azedra (iobenguane I-131) IV for treatment of pheochromocytoma and paraganglioma, affecting providers prescribing or administering the drug for AvMed members in North Carolina.

    Policy Summary
    PayerAvMed
    PolicyAzedra (iobenguane I-131) IV — Prior Authorization and Medical Necessity Criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit a signed prior authorization form with required supporting documentation (labs, imaging, weight, pregnancy test when applicable) to request coverage for one dosimetric dose and two therapeutic doses.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 months / 3Authorized duration / doses
    A9590HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18,500 MBqTherapeutic dose (>62.5 kg)
    185-222 MBqDosimetric dose (>50 kg)
    ≥12Minimum age

    Coverage Criteria for Azedra (iobenguane I-131)

    Initial Therapy

    Covered when ALL of the following are met

    Patient eligibility and administrative: Member is at least 12 years of age; requesting provider is an oncologist; prescriber signature on the prior authorization form as required; for females of reproductive potential a negative pregnancy test has been confirmed; member has a life expectancy of at least 6 months; Karnofsky Performance Status ≥ 60; provider will initiate appropriate thyroid blockade starting at least 24 hours before and continue for 10 days after each Azedra dose

    Administrative and baseline clinical requirements

    Disease characteristics: Member has locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma; disease is iobenguane scan–positive in at least one tumor site; condition requires systemic chemotherapy; disease has progressed from previous therapy OR member is not a candidate for chemotherapy (e.g., sunitinib) or other curative therapies

    Indication-specific requirements

    Prior radiation and hypertension exclusions: Member has NOT received radiation therapy (including systemic radiotherapy or external beam) resulting in >25% bone marrow exposure; member does NOT have uncontrolled or unstable hypertension

    Safety exclusions related to prior radiation exposure and blood pressure

    Dosing schedule and monitoring: Treatment consists of one imaging dosimetric dose followed by two therapeutic doses administered at least 90 days apart; provider will follow recommended weight-based dosing and scan protocol to calculate therapeutic dosing; therapeutic dose reductions may be required based on estimated critical organ absorption limits

    See dosing table for exact MBq/mCi per weight and imaging schedule

    Coverage for Azedra (iobenguane I-131) is limited to a single authorization period of 6 months, which covers a total of 3 doses — one imaging dosimetric dose followed by two therapeutic doses administered at least 90 days apart. Authorizations may NOT be renewed beyond this 6-month period.

    Requests that do not meet all listed approval criteria are not eligible for coverage. Key required criteria include documented iobenguane scan positivity in at least one tumor site and absence of uncontrolled/unstable hypertension, as well as other administrative and clinical requirements (age ≥ 12 years, oncologist requester, negative pregnancy test for females of reproductive potential, life expectancy ≥ 6 months, Karnofsky ≥ 60, appropriate thyroid blockade, etc.).

    Coding and Dosing Details

    Covered HCPCS CodesHCPCSCovered
    A9590Iodine I-131 iobenguane (Azedra) IV
    Weight-based dosing thresholds
    >62.5 kgTherapeutic dose = 18,500 MBq (500 mCi) per dose
    62.5 kg or lessTherapeutic dose = 296 MBq/kg (8 mCi/kg) per dose
    >50 kgDosimetric dose = 185–222 MBq (5–6 mCi)
    50 kg or lessDosimetric dose = 3.7 MBq/kg (0.1 mCi/kg)

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Azedra (iobenguane I-131) IV (HCPCS A9590). The prescribing physician must sign and clearly print their name on the prior authorization request (preprinted stamps are not valid). Fax the completed form to 1-877-535-1391. Incomplete, incorrect, or illegible information (including missing phone/fax numbers) may delay processing or lead to denial.

    • Prior authorization required for HCPCS A9590 (Azedra).
    • Prescribing physician signature mandatory; preprinted stamps not acceptable.
    • Fax completed request to 1-877-535-1391.
    Prior Authorization

    Authorization Duration

    Coverage will be provided for a single authorization period of 6 months to allow for up to 3 doses (one imaging/dosimetric dose followed by two therapeutic doses given at least 90 days apart). Authorization may not be renewed.

    • Authorization duration: 6 months.

    Covered Dosimetric and Therapeutic Regimens

    Dose componentWeight thresholdMBqNotes
    Initial imaging (dosimetric) dose
    Patients > 50 kg
    185–222 MBq
    Administer intravenously; used to perform scans to calculate therapeutic dosing (acquire whole body images Day 0, Day 1–2, and Days 2–5 as described).
    Initial imaging (dosimetric) dose
    Patients ≤ 50 kg
    3.7 MBq/kg
    Administer intravenously; weight-based per kg dosing for patients 50 kg or less; used to perform scans to calculate therapeutic dosing.
    Therapeutic dose (per dose)
    Patients > 62.5 kg
    18,500 MBq
    Administer as two intravenous doses at least 90 days apart; may require reduction based on estimated critical organ absorption limits.
    Therapeutic dose (per dose)
    Patients ≤ 62.5 kg
    296 MBq/kg
    Administer as two intravenous doses at least 90 days apart; weight-based (per kg) dosing for patients 62.5 kg or less; may require reduction based on organ absorption limits.

    Line of Therapy

    second-line

    Line of therapy: Member's condition has progressed from previous therapy OR member is not a candidate for chemotherapy (e.g., sunitinib) or other curative therapies

    Indicates use after progression or when chemotherapy/curative options are not appropriate

    Definitions and Dose Terms

    Dosimetric dose
    DefinitionDosimetric dose: an initial imaging dose used to perform scans and calculate therapeutic dosing.
    Dose for >50 kg185–222 MBq (5–6 mCi) intravenously
    Dose for ≤50 kg3.7 MBq/kg (0.1 mCi/kg) intravenously
    PurposeAcquire serial whole-body gamma camera images (Day 0 within 1 hour pre-voiding, Day 1–2 post-voiding, Days 2–5 post-voiding) to calculate therapeutic dose
    Therapeutic dose
    DefinitionTherapeutic dose: the calculated treatment dose given as two intravenous doses at least 90 days apart.
    Dose for >62.5 kg

    Background

    Azedra (iobenguane I-131) is a radiotherapeutic agent used for both an initial imaging dosimetric scan and for targeted systemic radiotherapy in patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma that are iobenguane scan-positive. Treatment consists of a single dosimetric imaging dose to calculate therapeutic dosing followed by two therapeutic doses given at least 90 days apart; dosing and dose reductions are determined by patient weight and estimated critical organ absorption limits.

    Policy Summary
    PayerAvMed
    PolicyAzedra (iobenguane I-131) IV — Prior Authorization and Medical Necessity Criteria
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit a signed prior authorization form with required supporting documentation (labs, imaging, weight, pregnancy test when applicable) to request coverage for one dosimetric dose and two therapeutic doses.
    SourceLink
    On This Page
    Coverage Criteria for Azedra (iobenguane I-131)Coding and Dosing DetailsProvider Actions, Documentation, and AuthorizationCovered Dosimetric and Therapeutic RegimensLine of TherapyDefinitions and Dose TermsBackground
  1. Maximum doses covered: 3 (1 dosimetric + 2 therapeutic, therapeutic doses ≥90 days apart).
  2. Authorization is non-renewable.
  3. Documentation Required

    Required Supporting Documentation

    Provide complete supporting documentation to substantiate each approval criterion. This includes relevant lab results, diagnostic imaging reports (including evidence of iobenguane scan-positivity), chart notes, weight and date weight obtained, dosing schedule, diagnosis and ICD code, and documentation of prior therapies. Missing or insufficient documentation may delay or result in denial.

    • Include weight and date weight obtained, dosing schedule, diagnosis, and ICD code.
    • Attach lab results, diagnostic imaging (e.g., scans showing iobenguane positivity), and chart notes.
    • Document prior therapies; prior therapy verification may be performed via pharmacy claims or chart review.
    Denial Risk

    Sample and Prior Therapy Verification / Incomplete Documentation Risk

    Use of samples to initiate therapy does not meet preauthorization criteria. Previous therapies will be verified via pharmacy paid claims or submitted chart notes. If information provided is not complete, correct, or legible, authorization can be delayed or denied.

    • Samples may not be used to meet preauthorization requirements.
    • Plan may verify prior therapies through pharmacy claims or chart documentation.
    • Incomplete/illegible requests may be delayed or denied.
    18,500 MBq (500 mCi) per dose, administered for 2 doses at least 90 days apart
    Dose for ≤62.5 kg296 MBq/kg (8 mCi/kg) per dose, administered for 2 doses at least 90 days apart
    Dose modificationTherapeutic dose reductions may be required based on calculated estimated critical organ absorption limits